Maxar Technologies still has a lot to prove, says National Bank

While Maxar Technologies (Maxar Technologies Stock Quote, Chart TSX, NYSE:MAXR) delivered better-than-expected first quarter results, National Bank analyst Richard Tse thinks the company still has a ways to go to reach a point of consistent execution.

In a daily bulletin to clients on Friday, Tse maintained his “Sector Perform” rating while raising his target price from $6.00 to $7.00. (All figures in US dollars.)

Space technology company Maxar released its first quarter ended March 31, 2019, financials on May 9, coming in with revenue of $504-million versus Tse’s estimate of $458 million and Adjusted EBITDA of $117 million compared to Tse’s $96 million and margins improving from 17 per cent to 23 per cent.

Tse noted that Maxar’s order backlog shrank from $2.4 billion last quarter to $1.9 billion, which the analyst says suggests that the outlook for the remainder of the year will be challenged.

Maxar announced in January that it had sustained a fatal defect in its WorldView4 satellite, set to be the company’s primary money-maker in its Imagery segment. Since then, Maxar has stated that it will receive $183 million from insurance proceeds, yet Tse says that the money covers only “a fraction” of the potential value contribution lost and that debt remains a serious issue for the company.

“While Management has laid out another round of actions including further cost reduction and restructuring along with the insurance proceeds of $183 million from the failure of WorldView4, recent history suggests investors should stay clear until we see some steady execution,” says Tse.

The analyst is calling for 2019 revenue and EBITDA of $1.97-billion and $491 million, respectively, while his $7.00 target represented a projected return of six per cent at the time of publication.

Tagged with: maxr
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Acumen Capital likes NeuPath Health right now

Acumen Capital analyst Nick Corcoran has initiated coverage of NeuPath Health (NeuPath Health Stock Quote, Chart, News, Analysts, Financials TSXV:NPTH)… [Read More]

10 hours ago

CIBC just raised its price target on Celestica

In an April 14 note, CIBC World Markets analyst Todd Coupland said he expects Celestica (Celestica Stock Quote, Chart, News,… [Read More]

10 hours ago

Amazon’s grand ambitions are now in full view, this analyst says

Roth Capital Markets analyst Rohit Kulkarni maintained his “Buy” rating and $285.00 target on Amazon (Amazon Stock Quote, Chart, News,… [Read More]

11 hours ago

This analyst just upgraded Quebecor

National Bank Financial analyst Adam Shine upgraded Quebecor (Quebecor Stock Quote, Chart, News, Analysts, Financials TSX:QBR.B) to “Outperform” from “Sector… [Read More]

11 hours ago

Sell Cogeco? Here’s what this analyst says

RBC Capital Markets analyst Drew McReynolds cut his target on Cogeco Communications (Cogeco Communications Stock Quote, Chart, News, Analysts, Financials… [Read More]

16 hours ago

CoreWeave is a stock for the long haul, this analyst says

Roth Capital Markets analyst Rohit Kulkarni raised his target on CoreWeave (CoreWeave Stock Quote, Chart, News, Analysts, Financials NASDAQ:CRWV) to… [Read More]

16 hours ago